Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders

a technology for chlamydia and related diseases, applied in the direction of drug compositions, immunoglobulins against animals/humans, peptides, etc., can solve the problems of inability to create an effective i>chlamydia /i>vaccine, inability to mechanism-based treatment of chlamydia /i>infections and chlamydia-related diseases, and inability to cure chlamydia-

Inactive Publication Date: 2015-03-19
WAKE FOREST UNIV HEALTH SCI INC
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]In one aspect the present invention provides a method of treating chlamydial infection and/or treating and/or preventing a disease or disorder caused by or associated with c

Problems solved by technology

However, untreated infections can cause numerous diseases such as infertility, osteoporosis, reactive arthritis, Alzheimer's disease, pelvic inflammatory disease and others.
Currently there is no mechanism-based treatment of Chlamydia infections and Chlamydia-related diseases.
Commonly used antibiotics can stop acute

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders
  • Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders
  • Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Activation of Epidermal Growth Factor (EGFR) is Required for Chlamydia trachomatis Development

[0113]Chlamydia trachomatis (C. trachomatis) is a clinically significant human pathogen and one of the leading causative agents of sexually transmitted diseases. As obligate intracellular bacteria, C. trachomatis has evolved strategies to redirect the host's signaling and resources for its own survival and propagation. Despite the clinical notoriety of Chlamydia infections, the molecular interactions between C. trachomatis and its host cell proteins remain elusive. In this study, we focused on the involvement of the host cell epidermal growth factor receptor (EGFR) in C. trachomatis attachment and development. A combination of molecular approaches, pharmacological agents and cell lines were used to demonstrate distinct functional requirements of EGFR in C. trachomatis infection. We show that C. trachomatis increases the phosphorylation of EGFR and of its downstream effectors PLCγ1, Akt and ...

example 2

Identification of Cancer Relevant Biomarkers of Infection Using Western Blot (WB) and Quantitative Mass Spectrometry (MS)

[0165]We initiated a series of targeted and discovery screening experiments to evaluate changes in protein, protein phosphorylation and protein oxidation in cells infected with C. trachomatis. Targeted analysis for a number of key signaling proteins is shown in FIG. 30. Important for this disclosure, the results revealed down-regulation of MKK4 at 12 and 24 hpi (hours post-infection) with C. trachomatis (FIG. 30). MKK4 is an important suppressor of metastasis. Down-regulation of MKK4 upon infection with C. trachomatis is significant for several reasons: i) it supports MKK4 as a potential biomarker of infection associated with unique developmental stages of C. trachomatis and cancer; ii) it opens opportunities for identifying MKK4-centered signaling networks that could be manipulated to prevent or combat chlamydial infections and cancer; and, iii) it could lead to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.

Description

STATEMENT OF PRIORITY[0001]This application claims the benefit, under 35 U.S.C. §119(e), of U.S. Provisional Application Ser. No. 61 / 877,898, filed Sep. 13, 2013, the entire contents of which are incorporated by reference herein.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to treatment / prevention of chlamydial infection and diseases and disorders associated with Chlamydia infection.[0004]2. Background Art[0005]Chlamydia is one of the most common sexually transmitted pathogens in the world, causing an estimated 92 million infections per year, with over 2.8 million infections in the US alone. The rate for chlamydial infection is 3.3 times higher in women than it is in men. It is estimated that nearly 3 million Americans are infected annually costing >$4 billion in healthcare. Most infected people have no symptoms. However, untreated infections can cause numerous diseases such as infertility, osteoporosis, reactive arthritis, Alzheime...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K45/06A61K31/517G01N33/574A61K31/7088C12Q1/68G01N33/569C07K16/28A61K31/5377
CPCA61K39/3955C07K16/2863A61K45/06A61K31/517A61K31/5377A61K31/7088G01N2333/71G01N33/56927G01N33/57492C07K2317/24C07K2317/21C12Q2600/154C12Q1/6883G01N2333/485G01N2800/52A61K31/712C07K2317/76C12Q1/689C12Q2600/158A61P15/00A61K2300/00A61K2039/505C07K16/32C12N15/1138C12N2310/11C12N2320/31G01N33/6893G01N2800/26
Inventor TSANG, ALLEN W.FURDUI, CRISTINA M.
Owner WAKE FOREST UNIV HEALTH SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap